Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Corcept Therapeutics

Clinical trials sponsored by Corcept Therapeutics, explained in plain language.

Corcept Therapeutics CORT NASDAQ

A commercial-stage pharmaceutical company developing drugs for severe metabolic and psychiatric disorders.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 5 Not yet finished but already full! 3 Completed 4 Terminated 1

New prostate cancer combo trial ends early

Disease control Terminated

This study tested a new drug called exicorilant (CORT125281) combined with enzalutamide in men with metastatic castration-resistant prostate cancer. The goal was to find a safe dose and check for side effects. The trial was terminated early, so results are limited. It involved 39…

Phase: PHASE1, PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 12:32 UTC